MİDE KANSERİ

Öz

Anahtar Kelimeler

• Mide Kanser

GASTRIC CANCER

Öz

Anahtar Kelimeler

• Gastric Cancer

Kaynakça

1. Gunderson LL, Donohue JH, Burch PA: Stomach, in Abeloff MD, Armitage JO, Lichter AS, et al: Clinical Oncology. New York, NY, Chuschill Livingstone, pp:1209-1241, 1995.
2. Green Lee RT, Murray T, Bolden S, et al. Cancer Statistics 2000. CA Cancer J Clin 50:7-33, 2000.
3. Wu-Williams AH, Yu MC, Mack TM. Life style, work, place, and stomach cancer by subsite in young men of Los Angeles County. Cancer Res 50:2569-2576, 1990.
4. Macdonald JS, Hill MC, Roberts IM. Gastric cancer: Epidemiology, pathology, detection and staging, in Ahlgren JD, Macdonald JS (eds): Gastrointestinal Oncology. Philadelphia, PA, J.B Lippincott, pp:151-158, 1992.
5. Kurtz RC, Sherlock P. The diagnosis of gastric cancer. Semin Oncol 12 (1): 11-8, 1985.
6. Scheiman JM, Cutler AF. Helicobacter pylori and gastric cancer. Am J Med 106 (2): 222-6, 1999.
7. Fenoglio-Preiser CM, Noffsinger AE, Belli J, et al. Pathologic and phenotypic features of gastric cancer. Semin Oncol 23 (3): 306, 1996.
8. Blot WJ, Devesa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265 (10): 1287-9, 1991.

9. Siewert JR, Böttcher K, Stein HJ, et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 228 (4): 449-61, 1998.
10. Nakamura K, Ueyama T, Yao T, et al. Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy. Cancer 70 (5): 1030-7, 1992.
11. Adachi Y, Yasuda K, Inomata M, et al. Pathology and prognosis of gastric carcinoma: well versus poorly differentiated type. Cancer 89 (7): 1418-24, 2000.
12. Fine G, Chan K: Alimentary tract. In: Kissane JM, ed. Anderson's Pathology. Vol 2. 8th ed. Saint Louis, Mo: CV Mosby, 1985, pp 1055-1095.
13. Maehara Y, Sakaguchi Y, Moriguchi S, et al. Signet ring cell carcinoma of the stomach. Cancer 69 (7): 1645-50, 1992.
14. Stomach. In: American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer, 2002, pp 106.
15. Roder JD, Böttcher K, Busch R, et al. Classification of regional lymph node metastasis from gastric carcinoma. German Gastric Cancer Study Group. Cancer 82 (4): 621-31, 1998.
16. Ichikura T, Tomimatsu S, Uefuji K, et al. Evaluation of the New American Joint Committee on Cancer/International Union against cancer classification of lymph node metastasis from gastric carcinoma in comparison with the Japanese classification. Cancer 86 (4): 553-8, 1999.
17. Bonenkamp JJ, Hermans J, Sasako M. Extended lymph-node dissection for gastric cancer. N Engl J Med, 340:908-914, 1999.
18. Kodama Y, Sugimachi K, soejima K et al. Evaluation of extensive lymph node dissection for carcinoma of the stomach. World J Surg 5:241-248, 1981.
19. Vezerdis MP, Wanebo HJ: Gastric cancer Surgical approach. In Gastrointestinal Oncology, eds Ahlgren JD ve Macdonald JS. Lippincott, Philadelphia, PA 159-170, 1992.
20. Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg, 75:110- , 1998.
21. Robertson CS, Chung SC, Woods SDS, et al.: A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg, 220:176-182, 1994.
22. Bunt AM, Hermans J, Smit VT: Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J Clin Oncol, 13:19-25, 1995.
23. Hermans J, Bonenkamp JJ, Boon MC et al.: Adjuvant therapy after curative resection for gastric cancer. Meta-analysis of randomized trials. J Clin Oncol 11:1441-1447, 1993.
24. Macdonald JS, Fleming TR, Peterson RF, et al.: Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group Study. Ann Surg Oncol, 2:488-494, 1995.
25. Earle CC, Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-asian patients: Revisiting a meta-analysis of randomized trials. Eur J Cancer, 35:1059-1064, 1999.
26. Macdonald JS, Smalley SR, Benedetti J et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med, 345:725-730, 2001.
27. Vanhoefer U, Rougier P, Wilke H, et al.: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18 (14): 2648-57, 2000.
28. Comis RL, Carter SK: Integration of chemotherapy into combined modality treatment of solid tumors. III. Gastric cancer. Cancer Treat Rev 1(3): 221-238, 1974.
29. Cullinan SA, Moertel CG, Fleming TR, et al.: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 253 (14): 2061-7, 1985.
30. MacDonald JS, Schein PS, Woolley PV, et al.: 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 93 (4): 533-6, 1980.
31. Douglass HO Jr, Lavin PT, Goudsmit A, et al.: An Eastern Cooperative Oncology Group evaluation of combinations of methyl- CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). J Clin Oncol 2 (12): 81, 1984.
32. Moertel CG, Rubin J, O'Connell MJ, et al.: A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 4 (7): 1053-7, 1986.
33. Waters JS, Norman A, Cunningham D, et al.: Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 80 (1-2): 269-72, 1999.
34. Ajani JA, Ota DM, Jackson DE: Current strategies in the management of locoregional and metastatic gastric carcinoma. Cancer (1 Suppl): 260-5, 1991.
35. Cascinu S, Labianca R, Alessandroni P, et al.: Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol 15 (11): 3313-9, 1997.
36. Ohtsu A, Shimada Y, Shirao K, et al.: Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21 (1): 54-9, 2003.
37. Preusser P, Wilke H, Achterrath W et al.: Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol, 7:1310-1317, 1989.
38. Kelsen D, Atiq OT, Saltz L, et al.: FAMTX versus etoposide, doxorubicin, and cisplatin: A random asignment trial in gastric cancer. J Clin Oncol, 10:541-548, 1992.
39. Wils JA, Klein HO, Wagener DJ, et al.: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin – A step ahead in the treatment of advanced gastric cancer: A trial of the European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol, 9:827-831, 1991.
40. Webb A, Cunningham D, Scarffe JH, et al.: Randomized trial comparing epirubicin, cicplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagealgastric cancer. J Clin Oncol, 15:261-267, 1997.
41. Ilson DH, Saltz L, Enzinger P et al.: Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol, 17:3270-3725, 1999.
42. Kettner E, Ridwelski K, Keilholz U, et al.: Docetakxel and cisplatin combination chemotherapy for advanced gastric cancer: Results of two phase II studies. Proc Am Soc Clin Oncol, 20:165A, 2001.
43. Green PH, O'Toole KM, Slonim D, et al.: Increasing incidence and excellent survival of patients with early gastric cancer: experience in a United States medical center. Am J Med 85 (5): 658-61, 1988.
44. Bozzetti F, Marubini E, Bonfanti G, et al.: Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg 230 (2): 170-8, 1999. ÖZGEÇMİŞ Prof. Dr. Erdem GÖKER Kişisel Bilgiler : 05.1961 Tarihinde İzmir’de Doğmuştur. Evlidir. Mesleki Bilgiler
45. Ege Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı Onkoloji Bilim Dalı 2000
46. Ege Üniversitesi Tıp Fakültesi Fakülte Kurulu Üyesi : Ege Üniversitesi İlaç Araştırma – Geliştirme Ve Farmakokinetik Araştırmalar Merkezi Müdür Yardımcısı 2000
47. Ege Üniversitesi Kanser Araştırma Ve Uygulama Merkezi Yönetim Kurulu Üyesi : Tıbbi Onkoloji Uzmanı ( 9 Eylül Üniversitesi Tıp Fakültesi Hematoloji-Onkoloji Bilim Dalı) 1995
48. Memorial Sloan-Kettering Kanser Merkezi, New York, ABD Hematoloji-Onkoloji Yandal İhtisası Slon-Kettering Enstitüsü Moleküler Farmakoloji Programı : İç Hastalıkları Uzmanı 1992
49. Ege Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dali Araştırma Görevlisi 1987
50. Çorum Kargı Merkez Sağlık Ocağı Tabibliği 1985
51. Hacettepe Üniversitesi Tıp Fakültesi 1978
52. İzmir Özel Türk Koleji 1972